» Articles » PMID: 11431323

Formation of Intracranial Tumors by Genetically Modified Human Astrocytes Defines Four Pathways Critical in the Development of Human Anaplastic Astrocytoma

Overview
Journal Cancer Res
Specialty Oncology
Date 2001 Jun 30
PMID 11431323
Citations 148
Authors
Affiliations
Soon will be listed here.
Abstract

The formation of human malignant gliomas is thought to involve the accumulation of multiple genetic alterations. To define the function of specific alterations in glioma formation, we serially introduced genetic alterations functionally equivalent to those noted in human malignant gliomas into normal human astrocytes (NHAs). We then monitored the ability of each of these alterations to contribute to the growth of otherwise genetically stable NHAs into intracranial malignant gliomas. Using this model, we show that expression of human telomerase catalytic component (hTERT), but not E7-mediated inactivation of pRb or E6/E7-mediated inactivation of p53/pRb, was sufficient to initiate the tumorigenic process by circumventing cellular senescence in astrocytes. hTERT expression, even in combination with inactivation of p53/pRb, did not transform astrocytes. These alterations together, however, cooperated with ras pathway activation (initiated by expression of mutant H-Ras), but not with phosphatidylinositol 3-kinase pathway activation (initiated by expression of myristoylated Akt) or epidermal growth factor receptor activation, to allow for the formation of intracranial tumors strongly resembling p53/pRb pathway-deficient, telomerase-positive, ras-activated human grade III anaplastic astrocytomas. These results identify four pathways as key in the development of human anaplastic astrocytomas.

Citing Articles

Cell-Based Glioma Models for Anticancer Drug Screening: From Conventional Adherent Cell Cultures to Tumor-Specific Three-Dimensional Constructs.

Lanskikh D, Kuziakova O, Baklanov I, Penkova A, Doroshenko V, Buriak I Cells. 2025; 13(24.

PMID: 39768176 PMC: 11674823. DOI: 10.3390/cells13242085.


MAP4 kinase-regulated reduced CLSTN1 expression in medulloblastoma is associated with increased invasiveness.

Sonmez E, Yan S, Lin M, Baumgartner M Sci Rep. 2025; 15(1):946.

PMID: 39762313 PMC: 11704044. DOI: 10.1038/s41598-024-84753-x.


HOXDeRNA activates a cancerous transcription program and super enhancers via genome-wide binding.

Deforzh E, Kharel P, Zhang Y, Karelin A, El Khayari A, Ivanov P Mol Cell. 2024; 84(20):3950-3966.e6.

PMID: 39383879 PMC: 11490371. DOI: 10.1016/j.molcel.2024.09.018.


Glioblastoma vulnerability to neddylation inhibition is dependent on PTEN status, and dysregulation of the cell cycle and DNA replication.

Taylor B, Tang N, Hao Y, Lee M, Peng S, Bybee R Neurooncol Adv. 2024; 6(1):vdae104.

PMID: 39119276 PMC: 11306933. DOI: 10.1093/noajnl/vdae104.


TRIM24 Cooperates with Ras Mutation to Drive Glioma Progression through snoRNA Recruitment of PHAX and DNA-PKcs.

Xu C, Chen G, Yu B, Sun B, Zhang Y, Zhang M Adv Sci (Weinh). 2024; 11(29):e2400023.

PMID: 38828688 PMC: 11304257. DOI: 10.1002/advs.202400023.